OYST Oyster Point Pharma Inc.

Biotech Analyst Ratings

Latest News

1. 05 May 2022 Oyster Point Pharma Reports First Quarter 2022 Financial Results and Recent Business Highlights

   • TYRVAYA® Nasal Spray Net Product Revenue of $2.7 Million in Q1'22
   • Approximately 19,000 TYRVAYA Prescriptions Filled During the Quarter, with Prescriptions Written by Over 4,500 Unique Eye Care Professionals
   • Expansion of Commercial Coverage for TYRVAYA, with Up to Approximately 95 Million Lives Covered to Date
   • Licensing Partner, Ji Xing Pharmaceuticals, Authorized to Conduct Phase 3 Clinical Trial of OC-01 in China
   • Continuing Enrollment of Subjects in the OLYMPIA Phase 2 Clinical Trial for Stage 1 Neurotrophic Keratopathy, with Study Results Expected in 2H 2022
   • Additional Pre-Clinical Studies Underway for Enriched Tear Film Gene Therapy to Target Stages 2 and 3 Neurotrophic Keratopathy
   • Conference Call and Webcast Scheduled for 4:30 pm ET Today
     

   PRINCETON…

   View Full Article
2. 03 May 2022 Oyster Point Pharma To Report First Quarter 2022 Financial Results On May 5, 2022

   PRINCETON, N.J., May 03, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (NASDAQ:OYST) a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced that it will report first quarter 2022 financial results on Thursday, May 5, 2022, after the market close. The announcement will be followed by a live audio webcast and conference call at 4:30 p.m. Eastern Time.
   

   Conference Call Details
   To access the live call by phone, please dial (855) 548-1220 (US/Canada) or (602) 563-8619 (International). The conference ID number is 4149318. A telephone replay will be available for approximately 7 days following the live conference…

   View Full Article
3. 27 April 2022 Oyster Point Pharma to Present New Analyses at the Association for Research in Vision and Ophthalmology (ARVO) 2022

   PRINCETON, N.J., April 27, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (NASDAQ:OYST), a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced the presentation of data analyses at the Association for Research in Vision and Ophthalmology (ARVO) 2022, being held on May 1-4.
   

   "We are pleased to be presenting new analyses of the pivotal trial data of TYRVAYA^® (varenicline solution) Nasal Spray for the treatment of the signs and symptoms of dry eye disease at ARVO, the premiere gathering for eye and vision scientists to share the latest research findings and collaborate on innovative solutions," said Marian…

   View Full Article
4. 19 April 2022 Oyster Point Pharma to Present New Clinical Data at the American Society of Cataract and Refractive Surgery (ASCRS) 2022

   PRINCETON, N.J., April 19, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (NASDAQ:OYST), a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced the presentation of data analyses at the American Society of Cataract and Refractive Surgery (ASCRS), being held on April 22-26.
   

   "The data we're presenting at ASCRS, the largest meeting of anterior segment surgeons, underscores Oyster Point Pharma's commitment to improving the care for people suffering with dry eye disease, a chronic condition that impacts an estimated 38 million people in the U.S.," said Marian Macsai, MD chief medical officer, Oyster…

   View Full Article
5. 17 March 2022 Oyster Point Pharma Announces Retirement of William J. Link From Board of Directors

   PRINCETON, N.J., March 17, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (NASDAQ:OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced that William J. Link, Ph.D., is retiring from Oyster Point's Board of Directors, effective as of March 17, 2022. Dr. Link will continue to serve as a consultant to the company.
   

   "On behalf of the entire Oyster Point organization, we are eternally thankful to Dr. Link for his leadership and significant contributions over the years," said Jeffrey Nau, M.M.S, Ph.D., president and chief executive officer, Oyster Point Pharma. "Even in his retirement, he will…

   View Full Article